

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	WO-2006009464-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 16:27
L2	0	WO-2006009465-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 16:28
L3	0	EP-1773397-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 16:28
L4	0	("2007015795").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/26 16:37
L5	1	("20070015795").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/26 16:44
L6	1	("20070009608").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/26 16:44
L7	123	polar adj head.clm.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 17:07
L8	85	polar adj head adj group.clm.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 17:08
L9	145	lipid adj compound.clm.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 17:08
L10	2	l8 and l9	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 17:08
L11	17	((ROLF) near2 (BERGE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/26 17:08
S15	161	((ANDREW) near2 (MILLER)).INV.	USPAT	OR	ON	2007/06/19 08:25
S16	292	((ANDREW) near2 (MILLER)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 09:28

EAST Search History

S17	128	((ANDREW) near2 (MILLER)).INV.	EPO; JPO; DERWENT	OR	ON	2006/11/16 09:28
S18	7	((MICHAEL) near2 (JORGENSEN)). INV.	EPO; JPO; DERWENT	OR	ON	2006/11/16 09:28
S19	12	((ROLF) near2 (BERGE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/20 09:55
S20	9	((ROLF) near2 (BERGE)).INV.	EPO; JPO; DERWENT	OR	ON	2006/11/16 09:29
S21	12	((ROLF) near2 (BERGE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 09:29
S22	12	((ROLF) near2 (BERGE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 09:29
S23	1	((JON) near2 (SKORVE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 09:30
S24	1	((JON) near2 (SKORVE)).INV.	EPO; JPO; DERWENT	OR	ON	2006/11/16 09:30
S25	3604	"514/54".CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 09:41
S26	2078	S25 and @ad<="20020620"	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:37
S27	226	S26 and phospholipid	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 11:44
S28	5	S27 and sulfur-containing	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 09:43
S29	57	S27 and sulfur	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 09:43
S31	1163	"536/53".CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 11:42
S32	600	S31 and @ad<="20020620"	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:38
S33	87	S32 and phospholipid	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:08

EAST Search History

S35	338	"554/85".CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:05
S36	77	S35 and @ad<="20020620"	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:08
S37	1142	"514/547".CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:07
S38	625	S37 and @ad<="20020620"	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:08
S39	93	S38 and phospholipid	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:08
S40	271	(564/1).CCLS.	US-PGPUB; USPAT	OR	OFF	2006/11/16 12:38
S41	124	S40 and @ad<="20020620"	US-PGPUB; USPAT; USOCR	OR	ON	2006/11/16 12:38
S42	0	WO-2003014073-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/20 09:47
S43	0	WO-03014073-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/19 08:26
S44	0	WO-200314073-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/19 08:28
S45	0	("2004192908").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/19 08:28
S46	1	("20040192908").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/19 08:28
S47	0	("2004/0192908").URPN.	USPAT	OR	ON	2007/06/19 08:34
S48	1	("5399353").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/19 08:34
S49	7	("5399353").URPN.	USPAT	OR	ON	2007/06/19 08:41
S50	0	WO-2003011252-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 16:25

EAST Search History

S54	1	("20040219202").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/20 09:49
S55	0	("2004/0219202").URPN.	USPAT	OR	ON	2007/06/20 09:51
S56	1	("4348329").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/20 09:51
S57	57	("4348329").URPN.	USPAT	OR	ON	2007/06/20 09:52
S58	0	("7064174").URPN.	USPAT	OR	ON	2007/06/20 09:53
S59	0	EP-0032622-\$.did.	USPAT	OR	ON	2007/06/20 09:54
S64	166	((ANDREW) near2 (MILLER)).INV.	USPAT	OR	ON	2007/06/20 09:56
S65	310	((ANDREW) near2 (MILLER)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/20 09:56
S66	148	((ANDREW) near2 (MILLER)).INV.	EPO; JPO; DERWENT	OR	ON	2007/06/20 09:56
S67	9	((MICHAEL) near2 (JORGENSEN)). INV.	EPO; JPO; DERWENT	OR	ON	2007/06/20 09:56
S68	15	((ROLF) near2 (BERGE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/20 09:56
S69	13	((ROLF) near2 (BERGE)).INV.	EPO; JPO; DERWENT	OR	ON	2007/06/20 09:56
S70	15	((ROLF) near2 (BERGE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/20 09:56
S71	15	((ROLF) near2 (BERGE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/20 09:56
S72	1	((JON) near2 (SKORVE)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/20 09:56
S73	2	((JON) near2 (SKORVE)).INV.	EPO; JPO; DERWENT	OR	ON	2007/06/20 09:56
S74	324	S64 or S65 or S66 or S67 or S68 or S69 or S70 or S71 or S72 or S73 and phospholipid	US-PGPUB; USPAT; USOCR	OR	ON	2007/06/20 09:58
S75	71	S74 and sulfur	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/20 09:59
S76	486	S64 or S65 or S66 or S67 or S68 or S69 or S70 or S71 or S72 or S73 and phospholipid	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/25 17:23

EAST Search History

S77	78	S76 and sulfur	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/20 10:43
S78	1	GB-2372502-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/20 10:54
S81	1	("20020188023").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/06/20 10:48
S82	145	lipid adj compound.clm.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/25 17:23
S83	114	phg.clm.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/26 17:07
S84	2	S82 and S83	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	ON	2007/06/25 17:24

FILE 'REGISTRY' ENTERED AT 15:36:55 ON 22 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3
DICTIONARY FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L2 (520)SEA FILE=REGISTRY SSS FUL L1
L3 STR

Compds. w/ at least one
phosphorous

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 21 Jun 2007 (20070621/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

L7 16 L6

=> sel hit 17 1-16 rn
E1 THROUGH E41 ASSIGNED

L7 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:79367 CAPLUS Full-text
DOCUMENT NUMBER: 144:156766
TITLE: Composition comprising plant, fish oils and non-oxidizable fatty acid entities and pharmaceutical or nutritional uses thereof
INVENTOR(S): Berge, Rolf
PATENT ASSIGNEE(S): Thia Medica AS, Norway
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006009464	A2	20060126	WO 2005-NO271	20050719
WO 2006009464	A3	20060824		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AY, BG, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
NO 2004003091	A	20060120	NO 2004-3091	20040719
NO 2004003093	A	20060120	NO 2004-3093	20040719
NO 2004005544	A	20060619	NO 2004-5544	20041217
AU 2005264781	A1	20060126	AU 2005-264781	20050719
CA 2574366	A1	20060126	CA 2005-2574366	20050719
EP 1784223	A2	20070516	EP 2005-772164	20050719
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,			


IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
US 2007009608 A1 20070111 US 2006-550129 20060509
PRIORITY APPLN. INFO.: NO 2004-3091 A 20040719
NO 2004-3093 A 20040719
NO 2004-5544 A 20041217
WO 2005-NO271 W 20050719

OTHER SOURCE(S): MARPAT 144:156766

AB The present invention concerns a composition prepared from a combination of plant oil and/or fish oil and a compound comprising non β -oxidizable fatty acid analogs, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, secondary stenosis, myocardial infarction, stroke, elevated blood pressure, endothelial dysfunction, procoagulant state, polycystic ovary syndrome, the metabolic syndrome, cancer, inflammatory disorders and proliferate skin disorders. The present invention also concerns an animal feed prepared from a combination of plant oil and/or fish oil and a compound comprising non β -oxidizable fatty acid analogs, the use of said feed for improving the body composition of an animal, and a product produced from said animal.

IT 636589-28-1
RL: BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition comprising plant, fish oils and non-oxidizable fatty acid entities and its pharmaceutical or nutritional uses thereof)
RN 636589-28-1 CAPLUS
CN 3,5,9-Trioxa-12-thia-4-phosphahexacosan-1-aminium, 4-hydroxy-N,N-trimethyl-10-oxo-7-[[[(tetradecylthio)acetyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:75330 CAPLUS Full-text
DOCUMENT NUMBER: 144:156735
TITLE: Composition containing protein material and compounds comprising non-oxidizable fatty acid entities
INVENTOR(S): Berge, Rolf
PATENT ASSIGNEE(S): Thia Medica AS, Norway
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006009465	A2	20060126	WO 2005-NO272	20050719
WO 2006009465	A3	20060914		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
NO 2004003091	A	20060120	NO 2004-3091	20040719
NO 2004003093	A	20060120	NO 2004-3093	20040719
NO 2004005544	A	20060619	NO 2004-5544	20041217
AU 2005264782	A1	20060126	AU 2005-264782	20050719
CA 2574381	A1	20060126	CA 2005-2574381	20050719
EP 1773397	A2	20070418	EP 2005-772070	20050719
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2007015795	A1	20070118	US 2006-550033	20060509
PRIORITY APPIN. INFO.:			NO 2004-3091	A 20040719
			NO 2004-3093	A 20040719
			NO 2004-5544	A 20041217
			WO 2005-NO272	W 20050719

OTHER SOURCE(S): MARPAT 144:156735

AB The present invention concerns a composition prepared from a combination of non-β-oxidizable fatty acid entities and a protein material, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, secondary stenosis, myocardial infarction, stroke, elevated blood pressure, endothelial dysfunction, procoagulant state, polycystic ovary syndrome, the metabolic syndrome, cancer, inflammatory disorders and proliferate skin disorders. An alternative embodiment of the invention includes oil in the composition. The present invention also concerns an animal feed prepared from a combination of a protein material and a compound comprising non-β-oxidizable fatty acid analogs, the use of said feed for improving the body composition of an animal, and a product produced from said animal.

IT 636589-28-1


RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(composition containing protein and non-oxidizable fatty acid entities for prevention and treatment of metabolic disorders and improvement of animal-based products)

RN 636589-28-1 CAPLUS

CN 3,5,9-Trioxa-12-thia-4-phosphahexacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(tetradecylthio)acetyl]oxy]]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:121684 CAPLUS Full-text
DOCUMENT NUMBER: 140:327017

TITLE: Engineered Lipids That Cross-Link the Inner and Outer Leaflets of Lipid Bilayers

AUTHOR(S): Halter, Michael; Nogata, Yoichi; Dannenberg, Oliver; Sasaki, Tomikazu; Vogel, Viola

CORPORATE SOURCE: Center for Nanotechnology, Departments of Bioengineering and Chemistry, University of Washington, Seattle, WA, 98195, USA

SOURCE: Langmuir (2004), 20(6), 2416-2423
CODEN: LANGD5; ISSN: 0743-7463

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:327017

AB The application of supported lipid bilayer systems as mol. sensors, diagnostic devices, and medical implants is limited by their lack of stability. In an effort to enhance the stability of supported lipid bilayers, three pairs of phosphatidylcholine lipids were designed to cross-link at the termini of their 2-position acyl chain upon the formation of lipid bilayers. The crosslinked lipids span the lipid bilayer, resembling naturally occurring bola-amphiphiles that stabilize archaeobacterial membranes against high temps. The three reactions investigated here include the acyl chain crosslinking between thiol and bromine groups, thiol and acryloyl groups, and cyclopentadiene and acryloyl groups. All three reactive lipid pairs were found to cross-link in liposomal membranes, as determined by thin-layer chromatog., ion-spray mass spectrometry, and 1H NMR. The monolayer film properties of the reactive amphiphiles were characterized by surface pressure-area isotherms and showed that stable monolayers formed at the air-water interface with limiting mol. areas comparable to that of pure saturated phosphatidylcholine lipids. Langmuir-Blodgett bilayers of dimyristoylphosphatidylcholine incorporating 15 mol % of the reactive thiol and acryloyl lipids had diffusion coeffs. comparable with pure dimyristoylphosphatidylcholine, while bilayers with more than 25 mol % of the reactive lipids were immobile, suggesting that interleaflet crosslinking of the lipids inhibited membrane diffusion. Our results show that the reactive lipids can cross-link within a lipid bilayer and are suitable for assembling supported lipid bilayers using Langmuir-Blodgett deposition. By using terminally reactive amphiphiles to build up supported lipid bilayers with crosslinked leaflets, bola-amphiphiles can be incorporated into asym. solid supported membranes to increase their stability in biosensor and medical implant applications.


IT 678139-86-1P 678139-88-3P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (engineered lipids that crosslink the inner and outer leaflets of lipid bilayers)


RN 678139-86-1 CAPLUS
 CN 3,5,8,42,45,47-Hexaoxa-25-thia-4,46-diphosphanonatetracontane-1,49-diaminium, 4,46-dihydroxy-N,N,N',N',N'-hexamethyl-9,41-dioxo-7-[(1-oxohexadecyl)oxymethyl]-43-[(1-oxotetradecyl)oxymethyl]-, bis(inner salt), 4,46-dioxide, (7R,43R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 678139-88-3 CAPLUS
 CN 3,5,8,21,42,45,47-Heptaosa-25-thia-4,46-diphosphanonatetracontane-1,49-diaminium, 4,46-dihydroxy-N,N,N',N',N'-hexamethyl-9,22,41-trioxo-7,43-bis[(1-oxohexadecyl)oxymethyl]-, bis(inner salt), 4,46-dioxide, (7R,43R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 678139-84-9P 678139-87-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT (Reactant or reagent)
 (engineered lipids that crosslink the inner and outer leaflets of lipid bilayers)
 RN 678139-84-9 CAPLUS
 CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxo-16-[(triphenylmethyl)thio]hexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 678139-87-2 CAPLUS
 CN 3,5,8,42,45,47-Hexaoxa-25-thia-4,46-diphosphanonatetracontane-1,49-diaminium, 4,46-dihydroxy-N,N,N',N',N'-hexamethyl-9,41-dioxo-7,43-bis[(1-oxohexadecyl)oxymethyl]-, bis(inner salt), 4,46-dioxide, (7R,43R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:2894 CAPLUS Full-text
DOCUMENT NUMBER: 140:42422
TITLE: Preparation of sulfur-containing phospholipid
triglyceride derivatives as antidiabetic agents
INVENTOR(S): Miller, Andrew David; Jorgensen, Michael Rael;
Berge, Rolf; Skorge, Jon
PATENT ASSIGNEE(S): Ic Vec Limited, UK; Thia Medica As
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000854	A1	20031231	WO 2003-GB2582	20030616
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490121	A1	20031231	CA 2003-2490121	20030616
AU 2003278602	A1	20040106	AU 2003-278602	20030616
EP 1515978	A1	20050323	EP 2003-740736	20030616
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1675229	A	20050928	CN 2003-817434	20030616
JP 2005529969	T	20051006	JP 2004-515006	20030616
NZ 537762	A	20070223	NZ 2003-537762	20030616
IN 2004CN02846	A	20060210	IN 2004-CN2846	20041215
NO 2004005562	A	20050217	NO 2004-5562	20041220
ZA 2005000558	A	20051017	ZA 2005-558	20050120
US 2006105987	A1	20060518	US 2005-518427	20050930
PRIORITY APPLN. INFO.:			GB 2002-14267	A 20020620

GB 2002-17506 A 20020729
WO 2003-GB2582 W 20030616

OTHER SOURCE(S): MARPAT 140:42422
GI




1

AB The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X-Y-Z-, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO₂, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula -(C(O)m)PHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties. Thus, esterified tetradecylthioacetic acid (TTA) phosphatidylcholines (PCs) and triacylglycerides (TAGs), e.g. I, were prepared. Effect of esterified and non-esterified TTA on palmitoyl-CoA oxidation in rat liver homogenate. Effect of esterified and non-esterified TTA on the mitochondrial carnitine palmitoyltransferase-II activity. Effect of esterified and non-esterified TTA on the 3-hydroxy-3-methylglutaryl-CoA synthase activity in rat liver homogenate. Effect of esterified and non-esterified TTA on the fatty acyl-CoA oxidase activity in rat liver homogenate. Effect of esterified and non-esterified TTA containing liposomes on plasma lipids in male Wistar rats. The compds. of the present invention (TTA-PC and TTA-TAG) have been demonstrated to increase fatty acid oxidation and decrease plasma and hepatic lipid levels.


IT 636589-28-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfur-containing phospholipid triglyceride derivs. as antidiabetic agents)
RN 636589-28-1 CAPLUS
CN 3,5,9-Trioxa-12-thia-4-phosphahexacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(tetradecylthio)acetyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- IT 636589-31-6P 636589-32-7P 636589-33-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of sulfur-containing phospholipid triglyceride derivs. as antidiabetic agents)
 RN 636589-31-6 CAPLUS
 CN Acetic acid, (11-tetradecynylthio)-, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



- RN 636589-32-7 CAPLUS
 CN Acetic acid, [(6Z)-6-tetradecynylthio]-, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



- RN 636589-33-8 CAPLUS
 CN Acetic acid, (11-tetradecynylthio)-, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



- IT 636589-29-2P 636589-30-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of sulfur-containing phospholipid triglyceride derivs. as antidiabetic agents)
 RN 636589-29-2 CAPLUS
 CN 3,5,9-Trioxa-12-thia-4-phosphahexacos-18-en-1-aminium, 4-hydroxy-N,N-trimethyl-10-oxo-7-[[[(6Z)-6-tetradecynylthio]acetyl]oxy]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A


PAGE 1-B



- RN 636589-30-5 CAPLUS
 CN 3,5,9-Trioxa-12-thia-4-phosphahexacos-23-yn-1-aminium, 4-hydroxy-N,N-trimethyl-10-oxo-7-[[[(11-tetradecynylthio)acetyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 $\equiv C-Et$

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:189315 CAPLUS Full-text
DOCUMENT NUMBER: 139:133726
TITLE: A chemoenzymatic route to quasisymmetrical chiral sulfoxides and their phospholipid derivatives
AUTHOR(S): Hodgson, Derek; Buist, Peter H.
CORPORATE SOURCE: Department of Chemistry, Carleton University, Ottawa, ON, K1S 5B6, Can.
SOURCE: Tetrahedron: Asymmetry (2003), 14(6), 641-644
CODEN: TASYE3; ISSN: 0957-4166
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:133726
AB The chain-length dependence of yeast $\Delta 9$ desaturase-mediated sulfoxidn. was examined Me (R)-9-thiahexadecanoate S-oxide (95% ee) and the corresponding phosphatidylcholine diester was synthesized.
IT 566170-58-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chemoenzymic preparation of quasisym. chiral sulfoxides and their phospholipid derivs. via bakers yeast mediated sulfoxidn.)
RN 566170-58-9 CAPLUS
CN 3,5,9-Trioxa-18-thia-4-phosphapentacosan-1-aminium, 7-[[8-[(R)-heptylsulfinyl]-1-oxooctyl]oxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4,18-dioxide, (7R,18R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:634613 CAPLUS Full-text
DOCUMENT NUMBER: 138:35002
TITLE: Origin of membrane dipole potential: Contribution of the phospholipid fatty acid chains
AUTHOR(S): Peterson, Uwe; Mannock, David A.; Lewis, Ruthven N. A. H.; Pohl, Peter; McElhaney, Ronald N.; Pohl, Elena E.
CORPORATE SOURCE: Institut für Medizinische Physik und Biophysik, Martin-Luther-Universität, Halle, 06097, Germany
SOURCE: Chemistry and Physics of Lipids (2002), 117(1-2), 19-27
CODEN: CPLIA4; ISSN: 0009-3084
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The large intrinsic membrane dipole potential, Φ_d , is important for protein insertion and functioning as well as for ion transport across natural and model membranes. However, the origin of Φ_d is controversial. From expts. carried out with lipid monolayers, a significant dependence on the fatty acid chain length is suggested, whereas in expts. with lipid bilayers, the contribution of addnl. -CH₂-groups seems negligibly small compared with that of the phospholipid carbonyl groups and lipid-bound water mols. To compare the impact of the -CH₂-groups of dipalmitoylphosphatidylcholine (DPPC) near and far from the glycerol backbone, the authors have varied the structure of DPPC by incorporation of sulfur atoms in place of methylene groups in different positions of the fatty acid chain. The Φ_d of sym. lipid bilayers containing one heteroatom was obtained from the charge relaxation of oppositely charged hydrophobic ions. The authors have found that the substitution for a S-atom of a -CH₂-group decreases Φ_d . The effect ($\Delta\Phi_d$ = -22.6 mV) is most pronounced for S-atoms near the lipid head group while a S-atom substitution in the C13- or C14-position of the hydrocarbon chain does not effect the bilayer dipole potential. Most probably $\Delta\Phi_d$ does not originate from an altered dipole potential of the acyl chain containing an heteroatom but is mediated by the disruption of chain packing, leading to a decreased d. of lipid dipoles in the membrane.
IT 478690-35-6 478690-37-8 478690-39-0
478690-41-4 478690-43-6
RL: PRP (Properties)
(phospholipid fatty acid chain methylene groups effect on membrane dipole potential)
RN 478690-35-6 CAPLUS
CN 3,5,8-Trioxa-11-thia-4-phosphatetracosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478690-37-8 CAPLUS
 CN 3,5,8-Trioxa-12-thia-4-phosphatetracosan-1-aminium,
 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]]-,
 inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478690-39-0 CAPLUS
 CN 3,5,8-Trioxa-15-thia-4-phosphatetracosan-1-aminium,
 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]]-,
 inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478690-41-4 CAPLUS
 CN 3,5,8-Trioxa-21-thia-4-phosphatetracosan-1-aminium,
 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]]-,
 inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478690-43-6 CAPLUS
 CN 3,5,8-Trioxa-22-thia-4-phosphatetracosan-1-aminium,
 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]]-,
 inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L7 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:180690 CAPLUS Full-text
 DOCUMENT NUMBER: 130:252555

TITLE: ω -Mercapto analogs of naturally occurring
 lipids

AUTHOR(S): Ohlsson, Jorgen; Magnusson, Goran
 CORPORATE SOURCE: Organic Chemistry 2, Center for Chemistry and
 Chemical Engineering, Lund University, Lund,
 SE-221 00, Swed.


SOURCE: Tetrahedron Letters (1999), 40(10), 2011-2014
 CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Analogs of natural lipids, where one of the alkyl chains carries a terminal
 thiol functionality, were prepared by N- or O-acylation of sphingosine or
 monoacylglycerol derivs., resp., thus creating lipid mimics, e.g. I, suitable
 for anchoring to gold surfaces.

IT 221623-70-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT (Reactant or reagent)


(preparation of ω -mercapto analogs of naturally occurring lipids
 and glycolipids)

RN 221623-70-7 CAPLUS

CN Hexadecanoic acid, 16-(acetylthio)-, (1R)-1-[[[(1-oxohexadecyl)oxy]methyl]-2-(phosphonoxy)ethyl ester (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



REFERENCE COUNT:

17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 16 CAPIUS. COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:692877 CAPIUS Full-text
DOCUMENT NUMBER: 126:47447
TITLE: Microstructure formation properties of 1,2-bis(15-thia-pentacosyl-10,12-diynyl)-sn-3-phosphocholine: an acyl chain modified diacetylenic phospholipid

AUTHOR(S): Markowitz, Michael A.; Singh, Alok
CORPORATE SOURCE: Laboratory for Molecular Interfacial Interactions, Code 6930, Center for Bio/Molecular Science and Engineering, Naval Research Laboratory, Washington, USA
SOURCE: Chemistry and Physics of Lipids (1996), 84(1), 65-74
CODEN: CPLIAM; ISSN: 0009-3084

PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English


AB An acyl chain modified diacetylenic phospholipid containing a sulfur beta to the diacetylene, 1,2-bis(15-thia-pentacosyl-10,12-diynyl)-sn-3-phosphocholine, was synthesized. Comparisons of the UV spectra of the lipid, the diacetylenic carboxylic acid precursor, and the unmodified diacetylenic lipid 1,2-bis(tricosyl-10,12-diynyl)-sn-3-phosphocholine reveal that the sulfur acts as an auxochrome resulting in bathochromic shifts and higher intensities for the absorption peaks. Differential scanning calorimetry was used to determine the acyl chain melting transition temps. of 1,2-bis(15-thia-pentacosyl-10,12-diynyl)-sn-3-phosphocholine in water (31.2°C) and 70:30 ethanol:water mixture (28.7°C) and revealed that the lipid packed more homogeneously in the ethanol:water mixture. Subsequent dispersal of the lipid in water produced ribbons with diams. ranging from 0.01-0.1 µm while dispersal in 70:30 ethanol:water leads to formation of tubules with diams. ranging from 0.6-0.8 µm. A gel comprised of interwoven ribbons was formed from an equimolar mixture of the lipid and 1,2-bis(nonoyl)-sn-glycero-3-phosphocholine (DNPC) in 0.1 M aqueous NaCl.

IT 185059-68-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (microstructure formation properties of bis(thiapentacosadiynyl)phosphocholine)
RN 185059-68-1 CAPIUS
CN 3,5,9-Trioxa-24-thia-4-phosphatetetratriaconta-19,21-diyn-1-aminium, 7-[[14-(decylthio)-1-oxo-10,12-tetradecadiynyl]oxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



L7 ANSWER 9 OF 16 CAPIUS. COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:502549 CAPIUS Full-text
DOCUMENT NUMBER: 123:56493
TITLE: Synthesis of glycerophospholipid oligodeoxyribonucleotide conjugates
AUTHOR(S): Vinogradov, Serguei V.; Le Doan, Trung; Helene, Claude
CORPORATE SOURCE: Centre Biophysique Moleculaire, CNRS, Orleans, 45071, Fr.
SOURCE: Tetrahedron Letters (1995), 36(14), 2493-6
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB Chemical synthesis of modified glycerophospholipids I (R = H, CO2H) and their attachment to oligodeoxyribonucleotides via dithio linker is described.
IT 164733-08-8P 164733-09-9P 164733-10-2P 164733-11-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (synthesis of glycerophospholipid dithio-linked oligodeoxyribonucleotide conjugates)

RN 164733-08-8 CAPLUS
 CN Hexadecanoic acid, 4-hydroxy-9-(4-methoxyphenyl)-4-oxido-1-[[[1-oxo-6-
 [(triphenylmethyl)thio]hexyl]oxy]methyl]-9,9-diphenyl-3,5-dioxo-8-aza-
 4-phosphanon-1-yl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—CPh3

RN 164733-09-9 CAPLUS
 CN 9,13,15-Trioxa-2-thia-14-phosphaoctadecan-18-oic acid,
 14-hydroxy-17-[[[4-methoxyphenyl]diphenylmethyl]amino]-8-oxo-11-[[1-
 oxohexadecyl]oxy]-1,1,1-triphenyl-, methyl ester, 14-oxide,
 [R-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—CPh3

RN 164733-10-2 CAPLUS


CN Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-
 [[1-oxo-6-[(triphenylmethyl)thio]hexyl]oxy]ethyl ester, (R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 164733-11-3 CAPLUS
 CN 9,13,15-Trioxa-2-thia-14-phosphaoctadecan-18-oic acid,
 17-amino-14-hydroxy-8-oxo-11-[[1-oxohexadecyl]oxy]-1,1,1-triphenyl-,
 methyl ester, 14-oxide, [R-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:490647 CAPLUS Full-text
 DOCUMENT NUMBER: 119:90647
 TITLE: Design, synthesis, and properties of a
 photoactivatable membrane-spanning phospholipidic
 probe

AUTHOR(S): Delfino, Jose M.; Schreiber, Stuart L.; Richards,
 Frederic M.
 CORPORATE SOURCE: Dep. Mol. Biophys. Biochem., Yale Univ., New
 Haven, CT, 06511, USA
 SOURCE: Journal of the American Chemical Society (1993),
 115(9), 3458-74
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A new photochem. probe suitable for labeling deep into the hydrophobic core of
 membranes is described: bisphosphatidylethanolamine(trifluoromethyl)

ethylphenyldiazirine (I). This is a dipolar phospholipid provided with a covalently bonded chain designed to span the membrane and equipped with a centrally defined attachment point for the photolabeling group (trifluoromethylphenyldiazirine (TPD)). This mol. was designed to enhance the geometrical resolution of photochem. labeling of membrane proteins by locating the photoreactive functionality in the center of the bilayer. The remarkable chemical stability of the photoreactive group TPD allowed the design of a straightforward and convergent synthetic strategy. The key steps developed for mols. of this new general kind are (a) the mild and efficient coupling of 2 moieties of N-tBOC-protected lysophosphatidylethanolamine Me ester to the photoreactive sym. dicarboxylic fatty acid mediated by dicyclohexylcarbodiimide and (dimethylamino)pyridine and (b) the smooth deprotection of the phosphate and amino functionalities with sodium iodide and trifluoroacetic acid, resp., to yield the final product. I was successfully incorporated into small and large unilamellar vesicles of different lipid composition and prepared by a variety of procedures. The bilayer location of this reagent (transmembrane vs U-shaped conformations) was assayed by reaction of the amino groups at the polar heads of the bipolar phospholipid with selected membrane-impermeable reagents. Photolysis of the probe incorporated into vesicles occurs readily upon irradiation with UV light (near 360 nm). These loaded vesicles show adequate stability and appear uniform and unilamellar in electron micrographs. They undergo the fusion reaction with influenza virus as efficiently as reagent-free vesicles. Evidence is presented here that I and a reductively methylated form efficiently label the peptide ion channel form of gramicidin A (and a chemical analog) and the influenza virus hemagglutinin. I may help to identify transmembrane regions of integral membrane proteins and map the lipid-protein interface in a region known to be deep in the membrane. A new radioactive version of this reagent ([3H]-I has been recently used to ascertain that the HA2 subunit of influenza virus hemagglutinin inserts into the target membrane prior to fusion.

IT 149183-58-4P 149203-93-0P


RL: PREP (Preparation)

(preparation and demethylation from phosphotriester group with sodium iodide of)


RN 149183-58-4 CAPLUS

CN 5,7,10,38,41,43-Hexaoxa-23,25-dithia-2,46-diaza-6,42-diphosphahaptatetracontanedioic acid, 6,42-dimethoxy-11,37-dioxo-9,39-bis[[(1-oxotridecyl)oxy)methyl]-24-[4-{3-(trifluoromethyl)-3H-diazirin-3-yl}phenyl]-, bis(1,1-dimethylethyl) ester, 6,42-dioxide, [9R-(9R*,39R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 149203-93-0 CAPLUS

CN 5,7,10,38,41,43-Hexaoxa-23,25-dithia-2,46-diaza-6,42-diphosphahaptatetracontanedioic acid, 6,42-dimethoxy-11,37-dioxo-9,39-bis[[(1-oxotridecyl)oxy)methyl]-24-phenyl]-, bis(1,1-dimethylethyl) ester, 6,42-dioxide, [9R-(9R*,39R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 113297-40-8P 149203-95-2P

RL: PREP (Preparation)


(preparation and properties, as membrane-spanning phospholipid probe)

RN 113297-40-8 CAPLUS

CN 3,5,8-Trioxa-21,23-dithia-4-phosphapentatriacontan-35-oic acid, 1-amino-4-hydroxy-9-oxo-7-[[[(1-oxotetradecyl)oxy)methyl]-22-phenyl]-, 1-[[[(2-aminooctoxy)hydroxyphosphinyl]oxy)methyl]-2-[[[(1-oxotetradecyl)oxy]ethyl ester, 4-oxide, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 149203-95-2 CAPLUS
CN 3,5,8-Trioxa-21,23-dithia-4-phosphapentatriacontan-35-oic acid, 1-amino-4-hydroxy-9-oxo-7-[[[(1-oxotetradecyl)oxy]methyl]-22-[4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl]-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[[[(1-oxotetradecyl)oxy]ethyl ester, 4-oxide, [R-(R',R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 149203-94-1P 149226-61-9P
RL: PREP (Preparation)
(preparation of and tertiary butoxycarbonyl group removal from)
RN 149203-94-1 CAPLUS
CN 5,7,10,38,41,43-Hexaoxa-23,25-dithia-6,42-diphosphatetetracatanedioic acid, 6,42-dihydroxy-9,39-bis[[[(1-oxotetradecyl)oxy]methyl]-24-[4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl]-, bis(1,1-dimethylethyl) ester, 6,42-dioxide, [R-(R',R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 149226-61-9 CAPLUS
CN 5,7,10,38,41,43-Hexaoxa-23,25-dithia-2,46-diaza-6,42-diphosphatetetracatanedioic acid, 6,42-dihydroxy-11,37-dioxo-9,39-bis[[[(1-oxotetradecyl)oxy]methyl]-24-phenyl]-, bis(1,1-dimethylethyl) ester, 6,42-dioxide, [R-(R',R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 149204-00-2P 149204-01-3P 149204-02-4P


RL: PREP (Preparation)

(preparation of, photoactivatable bisphosphatidylethanolamine phenyldiazirine derivative as membrane-spanning probe in relation to)


RN 149204-00-2 CAPLUS

CN 3,5,8-Trioxa-21,23-dithia-4-phosphapentatriacontan-35-oic acid, 1-amino-4-methoxy-9-oxo-7-[[[1-oxotetradecyl]oxy]methyl]-22-phenyl-, 1-[[[(2-aminoethoxy)methoxyphosphinyl]oxy]methyl]-2-[[[1-oxotetradecyl]oxy]ethyl ester, 4-oxide, [7R-(7R*,35(1R*))]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 149204-01-3 CAPLUS


CN 3,5,8-Trioxa-21,23-dithia-4-phosphapentatriacontan-35-oic acid, 1-amino-4-hydroxy-9-oxo-7-[[[1-oxotetradecyl]oxy]methyl]-22-phenyl-, 1-[[[hydroxy[2-[(2,4,6-trinitrophenyl)amino]ethoxy]phosphinyl]oxy]methyl]-2-[[[1-oxotetradecyl]oxy]ethyl ester, 4-oxide, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 149204-02-4 CAPLUS


CN 3,5,8-Trioxa-21,23-dithia-4-phosphapentatriacontan-35-oic acid, 4-hydroxy-9-oxo-7-[[[1-oxotetradecyl]oxy]methyl]-22-phenyl-1-[(2,4,6-trinitrophenyl)amino]-, 1-[[[hydroxy[2-[(2,4,6-trinitrophenyl)amino]ethoxy]phosphinyl]oxy]methyl]-2-[[[1-oxotetradecyl]oxy]ethyl ester, 4-oxide, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:449085 CAPLUS Full-text
DOCUMENT NUMBER: 119:49085

TITLE: Synthesis of sulfur-substituted phosphatidylethanolamines and inhibition of protozoan cyclopropane fatty acid synthase
AUTHOR(S): Li, Ruoxin; Ganguli, Shovan; Pascal, Robert A., Jr.

CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA

SOURCE: Tetrahedron Letters (1993), 34(8), 1279-82
CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB The phosphatidylethanolamine I was prepared by chemical synthesis. I and its mono-S-Me derivative inhibit the cyclopropane fatty acid synthase from the parasitic protozoan Crithidia fasciculata.

IT 148693-65-6DP, mono-S-Me derivative 148693-65-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and inhibition by, of cyclopropane fatty acid synthetase)


RN 148693-65-6 CAPLUS

CN Octanoic acid, 8-(nonylthio)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 148693-65-6 CAPLUS

CN Octanoic acid, 8-(nonylthio)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:192131 CAPLUS Full-text
DOCUMENT NUMBER: 118:192131


TITLE: Sulfur-substituted phosphatidylethanolamines

AUTHOR(S): Li, Ruoxin; Pascal, Robert A., Jr.

CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA

SOURCE: Journal of Organic Chemistry (1993), 58(7), 1952-4
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Title compds, e.g. I (R = 9-, 10-, 11-, 12-thiastearoyl) were prepared from 01,02-isopropylidenedeglycerol in 7 steps.

IT 147071-25-8P 147071-26-9P 147071-27-0P


148693-65-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 147071-25-8 CAPLUS

CN Nonanoic acid, 9-(octylthio)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 147071-26-9 CAPLUS

CN Decanoic acid, 10-(heptylthio)-, 1-([[(2-aminoethoxy)hydroxyphosphinyl]oxy)methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 147071-27-0 CAPLUS

CN Undecanoic acid, 11-(hexylthio)-, 1-([[(2-aminoethoxy)hydroxyphosphinyl]oxy)methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 148693-65-6 CAPLUS

CN Octanoic acid, 8-(nonylthio)-, 1-([[(2-aminoethoxy)hydroxyphosphinyl]oxy)methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:420466 CAPLUS Full-text

DOCUMENT NUMBER: 113:20466

TITLE: Interactions of mammalian cells with lipid

dispersions containing novel metabolizable

cationic amphiphiles

Leventis, Rania; Silvius, John R.

CORPORATE SOURCE: Dep. Biochem., McGill Univ., Montreal, QC, H3G

1Y6, Can.

SOURCE:

Biochimica et Biophysica Acta, Biomembranes
(1990), 1023(1), 124-32

CODEN: BBMBBS; ISSN: 0005-2736

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB

Several novel cationic amphiphiles, based on a hydrophobic cholesteryl or dioleoylglyceryl moiety, have been prepared whose hydrophobic and cationic portions are linked by ester bonds to facilitate efficient degradation in animal cells. Dispersions combining such cationic species with phosphatidylethanolamine (PE), certain structural analogs of PE or diacylglycerol can mediate efficient transfer of both nonexchangeable lipid probes and the DNA plasmid pSV2cat into cultured mammalian (CV-1 and 3T3) cells. The abilities of different types of cationic lipid dispersions to mediate transfection of mammalian cells with pSV2cat could not be directly correlated with their abilities to coalesce with other membranes, as assessed by their ability to intermix lipids efficiently with large unilamellar phosphatidylcholine/phosphatidylserine vesicles in the presence or absence of DNA. The cytotoxicities toward CV-1 cells of dispersions combining PE with most of the degradable cationic amphiphiles studied here compare favorably with those reported previously for similar dispersions containing other types of cationic amphiphiles. Fluorescent analogs of 1/2 of the diacylglycerol-based cationic amphiphiles examined in this study are readily degraded after incorporation into CV-1 cells from PE/cationic lipid dispersions.

IT

108535-71-3

RL: ANST (Analytical study)

(palmitoylstearyl)glycerol derivative and homostearyl


phosphatidylcholine derivative preparation from)

RN 108535-71-3 CAPLUS


CN

3,5,8-Trioxa-21-thia-4-phosphatricosan-1-aminium, 23-[[[4-(7-(diethylamino)-4-methyl-2-oxo-2H-1-benzopyran-3-yl)phenyl]amino]-20-hexyl-4-hydroxy-N,N-trimethyl-9,23-dioxo-7-[[[1-oxo-1-hexadecyl]oxy]methyl]]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:167843 CAPLUS Full-text

DOCUMENT NUMBER: 108:167843

TITLE: An efficient method for the partial synthesis of

AUTHOR(S):	mixed-chain phosphatidylethanolamines Delfino, Jose M.; Schreiber, Stuart L.; Richards, Frederic M.
CORPORATE SOURCE:	Sterling Chem. Lab., Yale Univ., New Haven, CT, 06520, USA
SOURCE:	Tetrahedron Letters (1987), 28(21), 2327-30 CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 108:167843




AB A key step in the title synthesis was the acylation of myristoylphosphatidylethanolamine I (R = H) with R1CO₂H [R1 = (CH₂)₃Me, (CH₂)₁₂Me, (CH₂)₁₂CO₂H, Z-(CH₂)₇CH:CH(CH₂)₇Me, Z,Z-(CH₂)₇CH:CHCH₂CH:CH(CH₂)₄Me] in the presence of DCC and DMAP to give 79-84_g esters I (R = R1COO). The latter were deprotected with NaI in 2-butanone followed by CF₃CO₂H in CH₂Cl₂ to give the title compds. II.

IT 113788-14-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)

(preparation and deprotection of)

RN 113788-14-0 CAPLUS

5,7,10-Trioxa-2,3,25-dithia-2-aza-6-phosphaheptatriacontanedioic acid, 6-methoxy-11-oxo-9-[[[(:-oxotetradecyl)oxy]methyl]-24-phenyl]-, 1-(1,1-dimethylethyl) ester, 6-oxide (9CI) (CA INDEX NAME)




IT 113788-20-8P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 113788-20-8 CAPLUS

3,5,8-Trioxa-21,23-dithia-4-phosphapentatriacontan-35-oic acid,
1-amino-4-hydroxy-9-oxo-7-[[[1-oxotetradecyl]oxy]methyl]-22-phenyl-,
4-oxide (9CI) (CA INDEX NAME)



L7 ANSWER 15 OF 16 · CAPIUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 198B:112865 CAPIUS Full-text
DOCUMENT NUMBER: 108:112865
TITLE: Synthesis of a bipolar phosphatidylethanolamine:
a model compound for a membrane-spanning probe
AUTHOR(S): Delfino, Jose M.; Stankovic, Charles J.;
Schreiber, Stuart L.; Richards, Frederic M.
CORPORATE SOURCE: Sterling Chem. Lab., Yale Univ., New Haven, CT,
06520, USA
SOURCE: Tetrahedron Letters (1987), 28(21), 2323-6
CODEN: TELEAY; ISSN: 0040-4039.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:112865
GI



AB A general strategy for the synthesis of membrane-spanning bipolar phospholipids equipped with a reactive functional group probe of the membrane environment is described. The strategy is exemplified by the synthesis of a bisphosphatidylethanolamine I that is connected through a benzylidene thioacetal of the ω -hydroxy esters at the sn-2 position of the two phosphoglycerol termini.

IT
113297-39-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)


(preparation and deprotection of)

RN	113297-39-5	CAPLUS
----	-------------	--------


CN 5,7,10,37,40,42-Hexaoxa-23-thia-2,45-diaza-6,41-

diphosphahexatetracontanedioic acid, 6,41-dimethoxy-11,36-dioxo-9,38-bis[[(1-oxotetradecyl)oxylmethyl]-24-phenyl-, bis(1,1-dimethylethyl)

PAGE 1-B




PAGE 1-B




RN 108535-73-5 CAPLUS
CN 14,17,19-Trioxa-2-thia-18-phosphaheneicosan-21-aminium,
18-hydroxy-N,N,N-trimethyl-13-oxo-15-[[1-(1-oxohexadecyl)oxymethyl]-1-
(2,5,6-trimethyl-1,7-dioxo-1H,7H-pyrazolo[1,2-a]pyrazol-3-yl)-], inner
salt, 18-oxide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 108535-74-6 CAPLUS
CN 15,18,20-Trioxa-2-thia-19-phosphadocosan-22-aminium,
3-hexyl-19-hydroxy-N,N,N-trimethyl-14-oxo-16-[[1-(1-
oxohexadecyl)oxymethyl]-1-(2,5,6-trimethyl-1,7-dioxo-1H,7H-
pyrazolo[1,2-a]pyrazol-3-yl)-], inner salt, 19-oxide (9CI) (CA INDEX
NAME)

PAGE 1-A



35



FILE 'CAOLD' ENTERED AT 15:37:44 ON 22 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate
substance identification. Title keywords, authors, patent
assignees, and patent information, e.g., patent numbers, are
now searchable from 1907-1966. TIFF images of CA abstracts
printed between 1907-1966 are available in the PAGE
display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of
all substance data from the REGISTRY file. Enter HELP FIRST for
more information.

L8 0 L6


FILE 'MEDLINE' ENTERED AT 15:38:00 ON 22 JUN 2007

FILE 'BIOSIS' ENTERED AT 15:38:00 ON 22 JUN 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:38:00 ON 22 JUN 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

L9 0 L6

(FILE 'REGISTRY' ENTERED AT 15:34:06 ON 22 JUN 2007)
STR




NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM

36

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12


STEREO ATTRIBUTES: NONE
L2 (520)SEA FILE=REGISTRY SSS FUL L1
L3 STR



VAR G1=CH2/S/SE/O
NODE ATTRIBUTES:
NSPEC IS RC AT 21
CONNECT IS X2 RC AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L4 STR



VAR G1=CH2/S/SE/O
NODE ATTRIBUTES:
NSPEC IS RC AT 21
CONNECT IS X2 RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L5 109 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)

(FILE 'CAPLUS' ENTERED AT 15:38:15 ON 22 JUN 2007)

L10 39 S L5
L11 23 S L10 NOT L7
L12 18 S L11 AND PATENT/DT
L13 15 S L12 AND (PY<2002 OR AY<2002 OR PRY<2002)
L14 5 S L11 NOT L12
L15 1 S L14 NOT PY<2002
L16 16 S L13 OR L15

=> sel l16 1-16 hit rn
E1 THROUGH E38 ASSIGNED

L16 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1327112 CAPLUS Full-text
DOCUMENT NUMBER: 146:252028

TITLE: Synthesis of Boron Cluster Lipids:
closododecaborate as an Alternative Hydrophilic
Function of Boronated Liposomes for Neutron
Capture Therapy

AUTHOR(S): Lee, Jong-Dae; Ueno, Manabu; Miyajima, Yusuke;

CORPORATE SOURCE: Nakamura, Hiroyuki
Department of Chemistry, Faculty of Science,
Gakushuin University, Mejiro, Toshima-ku, Tokyo,

SOURCE: 171-8588, Japan
Organic Letters (2007), 9(2), 323-326
CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:252028

AB We succeeded in the synthesis of the double-tailed boron cluster lipids 4a-c
and 5a-c, which have a B12H11S moiety as a hydrophilic function, by S-
alkylation of B12H11SH (BSH) with bromoacetyl and chloroacetate derivs.
of diacylglycerols for a liposomal boron delivery system on neutron capture
therapy. Calcein encapsulation expts. revealed that the liposomes, prepared
from the boron cluster lipid 4b, DMPC, PEG-DSPE, and cholesterol, are stable
at 37 °C in FBS solution for 24 h.

IT 925698-19-7P 925698-21-1P 925698-23-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(synthesis of boron cluster lipids: closododecaborate as an
alternative hydrophilic function of boronated liposomes for neutron
capture therapy)

RN 925698-19-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 925698-18-6
CMF C36 H76 B12 N O6 S
CCI RIS

Ans. set limited to patent/non-patent docs. dated
prior to 2002


PAGE 1-A

CRN 925698-20-0
CMF C40 H84 B12 N O6 S
CCI RIS

PAGE 1-A




PAGE 2-A



CM 2

CRN 51-92-3
CMF C4 H12 N




RN 925698-21-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


39

PAGE 2-A



CM 2

CRN 51-92-3
CMF C4 H12 N




40

RN 925698-23-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 925698-22-2
CMF C44 H92 B12 N O6 S
CCI RIS


PAGE 1-A



PAGE 2-A



CM 2
CRN 51-92-3
CMF C4 H12 N



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:133230 CAPLUS Full-text
DOCUMENT NUMBER: 138:175891
TITLE: Fatty acid compounds, preparations, and uses thereof
INVENTOR(S): Najib-Fruchart, Jamila; Caumont-Bertrand, Karine
PATENT ASSIGNEE(S): Genfit, Fr.
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014073	A1	20030220	WO 2002-FR2831	20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
FR 2828487	A1	20030214	FR 2001-10645	20010809
FR 2828487	B1	20050527		
CA 2456288	A1	20030220	CA 2002-2456288	20020808
AU 2002342968	A1	20030224	AU 2002-342968	20020808
JP 2004537595	T	20041216	JP 2003-519023	20020808
EP 1673338	A1	20060628	EP 2002-779622	20020808
US 2004192908	A1	20040930	US 2004-484350	20040121
PRIORITY APPLN. INFO.:				
			FR 2001-10645	A 20010809
			WO 2002-FR2831	W 20020808


OTHER SOURCE(S): MARPAT 138:175891
AB The invention concerns novel mols., their preparation and their uses, in particular in the field of human and veterinary medicine and in cosmetics. The inventive compds. are partly fatty acid derivs. and exhibit advantageous

pharmacol. and cosmetic properties. The invention also concerns various uses of said compds., the pharmaceutical compns. containing them and methods for preparing them. The inventive compds. are useful in particular for preventing and/or treating dyslipidemias, cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, certain cancers, dermatol. diseases, and in cosmetics for fighting against skin aging and its effects notably against wrinkles and the like.


IT 31716-45-7P 497263-29-3P 497263-30-6P
497263-31-7P 497263-32-8P 497263-34-0P
497263-35-1P 497263-36-2P 497263-37-3P
497263-38-4P 497263-39-5P 497263-40-8P
497263-41-9P

RL: COS (Cosmetic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (fatty acid compds., preps., and uses thereof)


RN 31716-45-7 CAPLUS
CN Butanoic acid, 4-(dodecylthio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)




RN 497263-29-3 CAPLUS
CN Acetic acid, (tetradecylthio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)




RN 497263-30-6 CAPLUS
CN Hexanoic acid, 6-(decylthio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)




RN 497263-31-7 CAPLUS
CN Acetic acid, (tetradecylsulfinyl)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



RN 497263-32-8 CAPLUS
CN Acetic acid, (tetradecylsulfonyl)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)




RN 497263-34-0 CAPLUS
CN Hexadecanoic acid, 2-[(tetradecylthio)acetyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)



RN 497263-35-1 CAPLUS
CN 9,12-Octadecadienoic acid (9Z,12Z)-, 2-[(tetradecylthio)acetyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

PAGE 1-A







RN 497263-36-2 CAPLUS
CN Octadecanoic acid, 2-[[[(tetradecylthio)acetyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)




RN 497263-37-3 CAPLUS
CN 9-Octadecenoic acid (9Z)-, 2-[[[(tetradecylthio)acetyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 497263-38-4 CAPLUS
CN Tetradecanoic acid, 2-[[[(tetradecylthio)acetyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)




RN 497263-39-5 CAPLUS
CN Hexadecanoic acid, 2,3-bis[[[(tetradecylthio)acetyl]oxy]propyl ester (9CI) (CA INDEX NAME)




RN 497263-40-8 CAPLUS
CN 9-Octadecenoic acid (9Z)-, 3-[[[(1-oxohexadecyl)oxy]-2-[[[(tetradecylthio)acetyl]oxy]propyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 497263-41-9 CAPLUS
CN Hexadecanoic acid, 2-[[[(docosylthio)acetyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:63958 CAPLUS Full-text
DOCUMENT NUMBER: 134:131810
TITLE: Preparation of oligomeric amino acid derivatives useful as nitric oxide synthase inhibitors

INVENTOR(S): Webber, R. Keith; Reuppel, Melvin L.; Hansen, Donald W., Jr.; Hallinan, E. Ann; Hagen, Timothy J.; Pitzelle, Barnett S.
 PATENT ASSIGNEE(S): Monsanto Company, USA
 SOURCE: PCT Int. Appl., 311 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005748	A1	20010125	WO 2000-US19373	20000714


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPL. INFO.: US 1999-143867P P 19990715

AB Novel oligomeric amidino amino carboxylate derivs. [1a]f[1b]g[1c]h[1d]i [B is a linker group; f, g, h, and i are integers 0-5, with the proviso that the sum of f, g, h, and i must be at least two; 1a, 1b, 1c, and 1d are independently selected from a structure R3N:CYNR4-X-CR8(NR1R2)C1J2-A-R7 attached to linker B by replacement of a substituent group; J1, J2 = OH, alkoxy, SH, alkylthio, amino, alkylamino, etc.; A = O, imino group, S, heterocyclyl, etc.; R1, R2 = H, hydroxyalkyl, aminoalkyl, alkyl, hetero, heterocyclyl, cycloalkyl, etc. or R1R2N may form a ring; R3, R4 = H, OH, SH, alkoxy, alkylthio, CH2SO3-M+, CH2PO3-M+ (M+ is a pharmaceutically acceptable cation), etc. or R3 and R4 together form a group; R7 = H, aryl, heteroaralkyl, OH, alkyl, amino, etc.; R8 = H, hydroxyalkyl, haloalkyl, alkyl, formyl, C(O)-A-R7, etc.; X = alkylene, alkenylene, alkynylene, (CH2)p-Q-(CH2)r, where p = 1-3 and Q = O, CO, NHSO2, etc.; Y = alkyl, cycloalkyl, cycloalkenyl, alkylthioalkyl, etc. (with provisos)] were prepared as nitric oxide synthase inhibitors. 1,5-Bis[6-(1-iminoethyl)amino]-2-amino-2-methylhexanamido]pentane tetrahydrochloride is one of thirty-two compds. claimed.

IT 321849-63-2P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oligomeric amino acid derivs. useful as nitric oxide synthase inhibitors)
 RN 321849-63-2 CAPLUS
 CN L-Lysine, N6-(2-fluoro-1-iminoethyl)-, 4-[[[(2S)-2-amino-6-[[1-(hydroxyamino)ethylidene]amino]-1-oxohexyl]oxy]-2-[(2R)-2-amino-3-[[2-[[1-(iminoethyl)amino]ethyl]thio]-1-oxopropoxy]-3-[[[(2S)-2-amino-6-[[1-(iminoethyl)amino]-1-oxohexyl]oxy]butyl ester, octakis(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1
 CRN 321849-62-1
 CMF C35 H67 F N12 O9 S

Absolute stereochemistry.



CM 2
 CRN 104-15-4
 CMF C7 H8 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:367983 CAPLUS Full-text
 DOCUMENT NUMBER: 133:22412
 TITLE: Cationic lipids for use liposomes for drug delivery
 INVENTOR(S): Xiang, Gao
 PATENT ASSIGNEE(S): Vanderbilt University, USA
 SOURCE: PCT Int. Appl., 152 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000030444	A1	20000602	WO 1999-US27841	19991123
US 6656498	B1	20031202	US 1999-447688	19991123
US 2003049310	A1	20030313	US 2002-224706	20020820
US 7002042	B2	20060221		

W: AU, CA, JP
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE


US 2006057194	A1	20060316	US 2005-201496	20050811
US 7067697	B2	20060627	US 1998-109950P	P 19981125
PRIORITY APPL. INFO.:			<--	
			US 1998-110970P	P 19981204
			<--	
			US 1999-447688	A3 19991123
			<--	
			US 2002-224706	A1 20030820

OTHER SOURCE(S): MARPAT 133:22412
AB The present invention relates to synthetic cationic lipids, liposome formulations and the use of such compds. to introduce functional bioactive agents into cultured cells.

```
IT 272462-71-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
    RACT (Reactant or reagent)
```

FN	272462-71-2	CAPLUS
CN	9-Octadecenoic acid (9Z)-, (1R)-1-[[[2-(dimethylamino)ethyl]thio]acetate]	

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

PAGE 1-B

Me

1 REFERENCE COUNT: THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:326341 CAPLUS Full-text
DOCUMENT NUMBER: 125:17173
TITLE: Metal-silicon composite alkoxides and their
manufacture for glass surface treatment
INVENTOR(S): Iyanagi, Koichi
PATENT ASSIGNEE(S): Pola Kasei Kogyo KK, Japan; Pola Chemical
Industries, Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

49


CODEN: JKXXAF			
DOCUMENT TYPE:	Patent		
LANGUAGE:	Japanese		
FAMILY ACC. NUM. COUNT:	1		
PATENT INFORMATION:			
PATENT NO.	KIND	DATE	APPLICATION NO.
JP 08040722	A	19960213	JP 1994-195868
			19940728
			←--
JP 3485273	B2	20040113	JP 1994-195868
PRIORITY APPLN. INFO.:			19940728

OTHER SOURCE(S): MARPAT 125:17173
AB The alkoxides represent (R'O)4-nM[O(C)QOSi(Xa)(OR)3-a]n (M = Ti or Zr; R = alkyl; R' = C₅ alkyl; Q = hydrocarbyl or S-containing divalent hydrocarbyl group; X = monovalent hydrocarbyl; a = 0-2 integer; n = 1 or 2). The alkoxides may be prepared from organosilicon compds.

polymers may be prepared from organotin compounds. The articles, $\text{O}[\text{C}(\text{O}R')\text{C}(\text{O})\text{QS}1\text{-(Xa)}(\text{OR}')_3\text{-a and M}(\text{OR}')_4$ ($R' = \text{C}_5\text{H}_3\text{ alkyl}$), especially suitable for primers, give titania or zirconia coatings with high wear resistance.


IT 170291-29-9P
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent) (metal-silicon composite alkoxides for coating of titania or zirconia on glasses)

FN	170291-29-9	CAPLUS	
CN	Undecanoic acid, 11-[[3-(trimethoxysilyl)propylthio]-, oxdi-3,1,2-propanetriyl ester (9CI)	(CA INDEX NAME)	



PAGE 1-A

PAGE 1-B



L16 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: .. 1996:228499 CAPLUS Full-text
 DOCUMENT NUMBER: 124:263548
 TITLE: "Alkali-resistant coating compositions

50

INDEX NAME)

CRN 170291-30-2
CMF C42 H86 O15 S3 Si3

CMF C42 H86 015 S3 Si3

PAGE 1-A

$$\begin{array}{c} \text{OEt} \\ | \\ \text{EtO}-\text{Si}-(\text{CH}_2)_3-\text{S}-\text{C}(=\text{O})-\text{O}-\text{CH}_2 \\ | \quad | \\ \text{OEt} \quad \text{OEt} \end{array} \quad \begin{array}{c} \text{O} \\ || \\ \text{OEt}-\text{Si}-(\text{CH}_2)_3-\text{S}-\text{C}(=\text{O})-\text{O}-\text{CH}_2-\text{CH}-\text{O}-\text{C}(=\text{O}) \\ | \quad | \\ \text{OEt} \quad \text{OEt} \end{array}$$

PAGE 1-B


$$\begin{array}{c} \text{EtO} \\ | \\ \text{---S---} \\ | \\ \text{EtO} \end{array}$$

CRN 170291-29-9
CMF C74 H150 O21 S4 Si4


$$\begin{array}{c} \text{OMe} \\ | \\ \text{MeO}-\text{Si}-(\text{CH}_2)_3-\text{S}-(\text{CH}_2)_3-\text{S}-\text{C}(=\text{O})-\text{O}-\text{CH}_2 \\ | \quad | \\ \text{OMe} \quad \text{OMe} \end{array} \quad \begin{array}{c} \text{O} \\ || \\ \text{CH}-\text{O}-\text{C}-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}-\text{C}(=\text{O})-\text{O}-\text{C}- \\ | \quad | \quad | \quad | \\ \text{OMe} \quad \text{OMe} \quad \text{OMe} \quad \text{OMe} \end{array}$$
$$-(\text{CH}_2)_{10}-\text{S}-(\text{CH}_2)_3-\text{Si}(\text{OMe})_2$$

52

PAGE 1-A




PAGE 1-B



CM 2

CRN 681-84-5

CMF C4 H12 O4 Si



II

170291-29-9P 170291-30-2P 170291-32-4P

170231 23 3F 170231 30 2F 170231 32 4F
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation);

REACT (Reactant or reagent)

(manufacture and polymerization of)


RN 170291-29-9 CAPLUS

Undecanoic acid, 11-[[3-(trimethoxysilyl)propyl]thio]-, oxydi-3,1,2-propanetriyl ester (9CI) (CA INDEX NAME)


oxidi-3,1,2-propanetriyl ester (9CI)	(CA INDEX NAME)

CONFIDENTIAL (S) (FOUO) 100-442887-1176-238

PAGE 1-A




PAGE 1-B




RN 170291-30-2 CAPLUS

Butanoic acid, 4-[[[3-(triethoxysilyl)propyl]thio]-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 170291-32-4 CAPLUS

CA INDEX NAME	CA INDEX NAME	CA INDEX NAME
D-Glucitol, hexakis[3-[[3-(trimethoxysilyl)propyl]thio]propanoate]		


(9CI) (CA INDEX NAME)

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)
(56)
(57)
(58)
(59)
(60)
(61)
(62)
(63)
(64)
(65)
(66)
(67)
(68)
(69)
(70)
(71)
(72)
(73)
(74)
(75)
(76)
(77)
(78)
(79)
(80)
(81)
(82)
(83)
(84)
(85)
(86)
(87)
(88)
(89)
(90)
(91)
(92)
(93)
(94)
(95)
(96)
(97)
(98)
(99)
(100)


53

54

PAGE 1-A



PAGE 1-B



L16 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:780702 CAPLUS Full-text
DOCUMENT NUMBER: 123:317097
TITLE: Preparation of alkoxyasilanes for coupling agents
INVENTOR(S): Iyanagi, Koichi
PATENT ASSIGNEE(S): Pola Kasei Kogyo Kk, Japan
SOURCE: Jpn: Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07157492	A	19950620	JP 1993-304302	19931203
JP 3273842	B2	20020415	JP 1993-304302	19931203

PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 123:317097
AB Polyhydric alc. esters having COOSi(OR)3 (R = alkyl; Q = hydrocarbon, S- containing divalent organic group) residues are prepared Heating diglycerin tetra-10-undecenoate, 3- mercaptopropyltrimethoxysilane, and AIBN in C6H6 at reflux for 24 h gave corresponding tetra(alkoxysilylated) ester.
IT 170291-29-9P 170291-30-2P 170291-32-4P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)


55

(preparation of alkoxyasilanes for coupling agents)


RN 170291-29-9 CAPLUS

CN Undecanoic acid, 11-([3-(trimethoxysilyl)propyl]thio)-, oxydi-3,1,2-propanetriyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 170291-30-2 CAPLUS

CN Butanoic acid, 4-([3-(triethoxysilyl)propyl]thio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 170291-32-4 CAPLUS


CN D-Glucitol, hexakis([3-(trimethoxysilyl)propyl]thio]propanoate) (9CI) (CA INDEX NAME)

56

PAGE 1-A




PAGE 1-B



IT 31716-42-4
RL: USES (Uses)
(in polycarbonates moldings with vivid color)
RN 31716-42-4 CAPIUS
CN Propanoic acid, 3-(octadecylthio)-, 1,2,3-propanetriyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B


—Me

L16 ANSWER 9 OF 16 CAPIUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1985:26291 CAPIUS Full-text
DOCUMENT NUMBER: 102:26291
TITLE: Lubricant finishes for acrylic precursors for carbon fibers
PATENT ASSIGNEE(S): Takemoto Oil and Fat Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59116473	A	19840705	JP 1982-234306	19821222
JP 62057743	B	19871202	JP 1982-234306	19821222
PRIORITY APPLN. INFO.: <-->				

AB Title finishes contain a N-containing surfactant and an ester of a thio fatty acid RS(CH₂)_nCO₂H, (R = C₆-22 alkyl, alkenyl; n = 1-3) and an aliphatic dibasic acid having its two carboxyl groups bonded to an aliphatic polyhydric alc. containing 2-4 OH groups. The N-containing surfactant may be a tertiary amine oxide R1N(O)R2R3 (R1 = C₈-22 alkyl, alkenyl, C₂H₄OH; R2, R3 = C1-22 alkyl, alkenyl). This finish imparts excellent separability, smoothness, and antistatic properties to acrylic precursor fibers for carbon fibers. Thus, a composition containing C14H29SCH2CH2CO2CH2CMe2CH2CO2(CH2)4CO2CH2CMe2CH2CH2SC14H29 [93933-56-3], polyethylene glycol nonylphenyl ether, polyethylene glycol lauryl ether, ethoxylated hydrogenated castor oil isocetyl phosphate diethanolamine salt [94122-03-9], and dimethylaurylamine oxide [1643-20-5] was adhered to acrylic

PAGE 1-A



PAGE 1-B



L16 ANSWER 8 OF 16 CAPIUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:613787 CAPIUS Full-text
DOCUMENT NUMBER: 117:213787
TITLE: Polycarbonate compositions for vivid-colored moldings
INVENTOR(S): Asao, Toshiaki; Hosomi, Tatsuhide
PATENT ASSIGNEE(S): Mitsubishi Gas Chemical Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04120164	A	19920421	JP 1990-239028	19900911
PRIORITY APPLN. INFO.: <-->				


AB The title comps., useful for injection moldings, sheets, films, etc., contain 0.0001-0.3 phr anthraquinone dyes and 0.001-0.5 phr thio- or thioether-containing carboxylic acid esters. Thus, bisphenol A polycarbonate containing 0.00008 phr anthraquinone violet and 0.05 phr pentaerythritol tetrakis(3-laurylthiopropionate) was injection molded to a 3-mm sheet with a vivid violet color.

filaments. The coated filaments were then dried and heated to give yarns with small friction coefficient, good filament separability, and excellent melt resistance.


IT 93933-52-9
 RL: USES (Uses)
 (lubricant finishes, containing nitrogen compds., for acrylic precursors for carbon fibers)
 RN 93933-52-9 CAPLUS
 CN Octadecenylthio)-1-oxopropoxy)methyl]ethyl ester, (all-Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L16 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1983:18071 CAPLUS Full-text
 DOCUMENT NUMBER: 98:18071
 TITLE: Lubricant finishes for synthetic fibers
 PATENT ASSIGNEE(S): Matsumoto Yushi-Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57082573	A	19820524	JP 1980-156098	19801105
JP 61053473	B	19861118		


PRIORITY APPLN. INFO.: JP 1980-156098 19801105

AB Lubricant finishes containing an ester, amide, or thioester containing RSZ(CO)n groups, where R is C1-22 aliphatic or aromatic hydrocarbon group, Z is alkylene, and n is 1 or 2, are heat-resistant and useful for finishing synthetic fibers. Thus, 3 mol olefmercaptan-acrylic acid reaction product was esterified with 1 mol glycerol to give an ester (I) [83995-03-3]. A lubricant composition (A) containing 60% I was heated 4 h at 220° without fume generation, whereas severe fume generation occurred for a similar composition containing oleyl oleate instead of I. Filament frictional coefficient was low in finishing nylon filaments with A composition

IT 83995-03-3
 RL: USES (Uses)
 (lubricant finishes, heat-resistant, for nylon filaments)
 RN 83995-03-3 CAPLUS
 CN Propanoic acid, 3-(9-octadecenylthio)-, 1,2,3-propanetriyl ester, (Z,Z,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




L16 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1980:605661 CAPLUS Full-text
 DOCUMENT NUMBER: 93:205661
 TITLE: Stabilizers for synthetic polymers comprising 2,2,6,6-tetramethyl-4-piperidyl carboxylic acid ester, β-thioalkyl propionic acid ester and phenol
 INVENTOR(S): Haruna, Toru; Kubota, Naohiro; Minagawa, Motonobu; Shibata, Toshihiro
 PATENT ASSIGNEE(S): Argus Chemical Corp., USA
 SOURCE: U.S., 55 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4219463	A	19800826	US 1977-852254	19771117

JP 53073241 A 19780629 JP 1976-149092 19761210
 JP 55035416 B 19800913 JP 1976-149092 A 19761210
 PRIORITY APPLN. INFO.:
 AB Stabilizers for polymers contain tetramethylpiperidyl carboxylates, (alkylthio)propanoate esters, and hindered phenols. Thus, PVC [9002-86-2] containing DOP 48, epoxidized soybean oil 2, (C9H19CGH40)3P 0.2, Ca stearate 1, 2,2,6,6-tetramethyl-4-piperidyl benzoate [26275-88-7] 0.2, BHT 0.1, and trimethylolpropane tris[3-(octadecylthio)propanoate] (I) [31687-07-7] 0.1 phr has Weather-O-Meter exposure resistance 515 h, compared with 385 with S(CH2CH2CO2C12H25)2 in place of I.
 IT 31716-41-3 75518-84-2
 RL: PEP (Physical, engineering or chemical process); PROC (Process)
 RN 31716-41-3 CAPLUS
 CN Propanoic acid, 3-(dodecylthio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




—Me

RN 75518-84-2 CAPLUS
 CN D-Glucitol, hexakis[3-(octylthio)propanoate] (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L16 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1980:77427 CAPLUS Full-text
 DOCUMENT NUMBER: 92:77427
 TITLE: Heat stabilizers for thermoplastics
 INVENTOR(S): Minagawa, Motonobu; Nakahara, Yutaka; Haruna, Toru
 PATENT ASSIGNEE(S): Adeka Argus Chemical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54041948	B4	19790403	JP 1977-108098	19770908

AB Comps. of thermoplastics 100, polyphosphites having alkyl-substituted Ph groups with or without pentaerythritol residues 0.001-5, and thioalkanoic acid derivs. 0.0001-5 parts have good heat stability. Thus, a mixture of Profax 6501 [9003-07-0] 100, Ca stearate 0.2, octadecyl 3-(3,5-di-tert-butylphenyl)propanoate 0.1, pentaerythritol tetrakis[3-(3,5-di-tert-butylphenyl)propanoate] 0.2, and pentaerythritol bis[2,4-di-tert-butylphenyl phosphite] [26741-53-7] 0.1 part was extruded at 230-40°, pelletized, and injection molded at 250° and 475 kg/cm2 to give test pieces having heat stability in air at 160° 856 h and Hunter yellowness 8.4, compared with 267 and 11.3, resp., for a similar composition without I.
 IT 71137-00-3

RL: MOA (Modifier or additive use); USES (Uses)
 (heat stabilizers, containing polyphosphite esters, for thermoplastics)
 RN 71137-00-3 CAPLUS
 CN D-Glucitol, hexakis[3-(dodecylthio)propanoate] (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—CO₂H
—CH₂—CH₂—CO₂H

RN 58888-37-2 CAPLUS
CN 6,10-Dioxo-3,13-dithiapentadecanedioic acid, 8-
[[[(carboxymethyl)thio]acetyl]oxy]-5,11-dioxo- (9CI) (CA INDEX NAME)



RN 58888-38-3 CAPLUS
CN 6,10-Dioxo-3,13-dithiapentadecanedioic acid, 8-
[[[(carboxymethyl)thio]acetyl]oxy]-5,11-dioxo-, potassium salt (9CI)
(CA INDEX NAME)




L16 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1975:460609 CAPLUS Full-text
DOCUMENT NUMBER: 83:60609
TITLE: Heat-stable polyolefin resin composition
containing a glyceride or an alkyl thioalkanoic
acid
INVENTOR(S): Onishi, Akiyoshi; Fukuoka, Naohiko
PATENT ASSIGNEE(S): Mitsubishi Petrochemical Co., Ltd.; Shipuro Kasei
K. K.
SOURCE: Jpn. Tokkyo Koho, 7 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
JP 49023295 B 19740614 JP 1969-104891 19691227
<--

DE 2028240 A1 19701223 DE 1970-2028240 19700609
<--
DE 2028240 C3 19731122
DE 2028240 B2 19730322
PRIORITY APPLN. INFO.:
JP 1969-45912 A 19690611
<--
JP 1969-91184 A 19691115
<--
JP 1969-104890 A 19691227
<--
JP 1969-104891 A 19691227
<--
JP 1969-104892 A 19691227
<--
JP 1970-27132 A 19700331
<--
JP 1970-27133 A 19700331
<--

AB Heat-degradation-resistant polyolefin resin moldings are prepared by melt
mixing the polyolefin, such as polypropylene [9003-07-0] powder with 0.3% of a
glyceride of an alkylthioalkanoic acid (RSCnH₂nCO₂H; R=C8-30 alkyl group, and
n = 2-3), such as C8H₁₇SCH₂CH₂CO₂CH₂CH(O₂CCH₂CH₂SC8H₁₇)
[31716-40-2], or a mixture of 0.1% of a hindered phenol type antioxidant, such
as octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate [2082-79-3] and
0.2% of the glyceride before molding.
IT 31716-40-2

RL: USES (Uses)
RN 31716-40-2 CAPLUS
CN Propanoic acid, 3-(octylthio)-, 1,2,3-propanetriyl ester (9CI) (CA
INDEX NAME)



L16 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1971:65007 CAPLUS Full-text
DOCUMENT NUMBER: 74:65007
TITLE: Polyolefin compositions stabilized against thermal
decomposition
INVENTOR(S): Onishi, Akiyoshi; Fukuoka, Naohiko
PATENT ASSIGNEE(S): Mitsubishi Petrochemical Co., Ltd.; Shipro Kasei
Kaisha, Ltd.
SOURCE: Ger. Offen., 35 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
DE 2028240 A1 19701223 DE 1970-2028240 19700609
<--

DE 2028240	C3	19731122		
DE 2028240	B2	19730322		
JP 49023295	B	19740614	JP 1969-104891	19691227
JP 49046144	B	19741207		19700331
JP 49046145	B	19741207		19700331
US 3629194	A	19711221	US 1970-44656	19700608

PRIORITY APPLN. INFO.:

JP 1969-45912	A	19690611
JP 1969-91184	A	19691115
JP 1969-104890	A	19691227
JP 1969-104891	A	19691227
JP 1969-104892	A	19691227
JP 1970-27132	A	19700331
JP 1970-27133	A	19700331
JP 1970-104890	A	19691227
JP 1970-104891	A	19691227
JP 1970-104892	A	19691227


AB Polyolefins are stabilized against thermal decomposition with esters of ω-(alkylthio)alkanoic acids and glycols, thio ether glycols, trimethylolalkanes, glycerol, or pentaerythritol. Thus, isotactic polypropylene powder was combined with a stabilizer, granulated by extrusion, and injection molded into 0.5-mm films, which were aged in an air oven at 140°. The unstabilized polymer became brittle within 3 hr, while comps. containing 0.3 or 0.6% octamethylene bis[3-(dodecylthio)propionate] required 126 and 191 hr, resp., to become brittle. A combination of 0.2% pentaerythritol tetrakis[3-(dodecylthio)propionate] and 0.1% n-octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate stabilized the composition for >3000 hr.

IT 31716-40-2 31716-41-3 31716-42-4
31716-44-6 31716-45-7 31716-46-8
31716-47-9

RL: USES (Uses)


(stabilizers, for propene polymers)

RN 31716-40-2 CAPLUS
CN Propanoic acid, 3-(octylthio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



RN 31716-41-3 CAPLUS
CN Propanoic acid, 3-(dodecylthio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Me

RN 31716-42-4 CAPLUS
CN Propanoic acid, 3-(octadecylthio)-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

—Me

RN 31716-44-6 CAPLUS
CN Butyric acid, 3-(dodecylthio)-, 1,2,3-propanetriyl ester (8CI) (CA INDEX NAME)



69

70

FILE 'DISSABS' ENTERED AT 15:45:02 ON 22 JUN 2007
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

L19 22599 S "MILLER A"2/AU
 L20 2001 S "JORGENSEN M"2/AU
 L21 1106 S "BERGE R"2/AU
 L22 144 S "SKORVE J"2/AU
 L23 2 S L19 AND L20 AND L21 AND L22
 L24 51 S L19 AND (L20 OR L21 OR L22)
 L25 2 S L20 AND (L21 OR L22)
 L26 115 S L21 AND L22
 L27 428 SEA ABB=ON PUJ=ON (L19-L22 OR L24 OR L26) AND (PHG OR POLAR HEAD OR PHOSPHOLIPID? OR LYSOPHOSPHO LIPID? OR (PHOSPHO OR LYSOPHOSPHO) (W) LIPID? OR CERAMIDE OR MONACYLGLYCEROL OR TRIACYLGLYCEROL OR DIACYLGLYCEROL OR (MONACYL OR TRIACYL OR DIACYL) (W) GLYCEROL OR W(W) LINK? (W) (HG OR HEAD GROUP))
 L28 983 SEA ABB=ON PUJ=ON (L19-L22 OR L24 OR L26) AND (PHOSPHATIDYL? OR LIPID OR (PC OR PE OR PS OR PI OR PG OR PA) (S) PHOSPHATIDYL?)
 L29 140 SEA ABB=ON PUJ=ON (L27 OR L28) AND (SULFUR? OR SULPHUR? OR SULFAT? OR SULPHAT?)
 L30 89 S L29 AND (TREAT? OR THERAP? OR PREVENT?)
 L31 59 S L29 AND INHIBIT?
 L32 3 SEA ABB=ON PUJ=ON (L30 OR L31) AND (TOPICAL? OR PARENTAL? OR IV OR (I OR INTRA) (W) (V OR VENOUS?) OR INTRA(W) (ABDOMEN OR ABDOMIN? OR PERITONEAL?) OR INTRAPERITONEAL? OR PERITONEAL?)

L33 4 S L23 OR L25 OR L32
 L34 3 DUP REM L33 (1 DUPLICATE REMOVED)

L34 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2004:2894 CAPLUS Full-text
 DOCUMENT NUMBER: 140:42422

TITLE: Preparation of sulfur-containing phospholipid

INVENTOR(S): triglyceride derivatives as antidiabetic agents
 Miller, Andrew David; Jorgensen, Michael Rael; Berge, Rolf;


PATENT ASSIGNEE(S): Skorve, Jon
 SOURCE: Ic Vec Limited, UK; Thia Medica As
 PCT Int. Appl., 113 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000854	A1	20031231	WO 2003-GB2582	20030616
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, KS, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490121	A1	20031231	CA 2003-2490121	20030616

AU 2003278602 A1 20040106 AU 2003-278602 20030616
 EP 1515978 A1 20050323 EP 2003-740736 20030616
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1675229 A 20050928 CN 2003-817434 20030616
 JP 2005529969 T 20051006 JP 2004-515006 20030616
 NZ 537762 A 20070223 NZ 2003-537762 20030616
 IN 2004CN02846 A 20060210 IN 2004-CN2846 20041215
 NO 2004005562 A 20050217 NO 2004-5562 20041220
 ZA 2005000558 A 20051017 ZA 2005-558 20050120
 US 2006105987 A1 20060518 US 2005-518427 20050930
 PRIORITY APPLN. INFO.: GB 2002-14267 A 20020620

OTHER SOURCE(S): MARPAT 140:42422
 GI GB 2002-17506 A 20020729
 WO 2003-GB2582 W 20030616



AB The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X-Y-Z-, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula -[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties. Thus, esterified tetradecylthioacetic acid (TTA) phosphatidylcholines (PCs) and triacylglycerides (TAGs), e.g. I, were prepared. Effect of esterified and non-esterified TTA on palmitoyl-CoA oxidation in rat liver homogenate. Effect of esterified and non-esterified TTA on the mitochondrial carnitine palmitoyltransferase-II activity. Effect of esterified and non-esterified TTA on the 3-hydroxy-3-methylglutaryl-CoA synthase activity in rat liver homogenate. Effect of esterified and non-esterified TTA on the fatty acyl-CoA oxidase activity in rat liver homogenate. Effect of esterified and non-esterified TTA containing liposomes on plasma lipids in male Wistar rats. The compds. of the present invention (TTA-PC and TTA-TAG) have been demonstrated to increase fatty acid oxidation and decrease plasma and hepatic lipid levels.

REFERENCE COUNT: 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 3 MEDLINE on STN
 ACCESSION NUMBER: 2001610006 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 11684079
 TITLE: Sustained retention of tetradecylthioacetic acid after local delivery reduces angioplasty-induced coronary stenosis in the minipig.

AUTHOR: Pettersen R J; Muna Z A; Kuiper K K; Svendsen E; Muller F; Aukrust P; Berge R K; Nordrehaug J E
CORPORATE SOURCE: Department of Heart Disease, Haukeland University Hospital, N-5021, Bergen, Norway.. rpet@haukland.no
SOURCE: Cardiovascular research, (2001 Nov) Vol. 52, No. 2, pp. 306-13.
JOURNAL CODE: 0077427. ISSN: 0008-6363.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200201
ENTRY DATE: Entered STN: 2 Nov 2001
Last Updated on STN: 25 Jan 2002
Entered Medline: 7 Jan 2002

AB OBJECTIVE: The sulfur containing tetracyclthioacetic acid (TTA) has a profound effect on lipid metabolism and may also exert antioxidant and anti-inflammatory actions and thereby counteract coronary stenosis after angioplasty balloon injury. This study examined the possible modulatory effects of TTA, delivered locally, on coronary stenosis in minipigs and the underlying mechanisms of action. METHODS: Coronary balloon angioplasty injury using an oversized balloon was performed to 40 coronary arteries (20 minipigs, Sus Scrofa, Gammelsoed) followed by delivery of placebo or TTA via a local drug delivery balloon catheter. TTA was radiolabelled in four pigs. Quantitative coronary angiography and intracoronary ultrasound (ICUS) were performed before and after injury, and after 4 weeks of follow-up. The arteries were examined with histomorphometry. The antioxidant and anti-inflammatory effects of TTA were examined on LDL oxidation and stimulated release of interleukin (IL)-2 and IL-10 in human peripheral blood mononuclear cells (PBMC), respectively. RESULTS: Radioactive TTA was present in the coronary wall after 4 weeks. Angiographic minimal luminal diameter (mean+/- S.E.M.) in the placebo and TTA group was 1.3+/-0.1 vs. 2.2+/-0.2 mm (P<0.01) at follow-up, stenosis rate was 55 and 20% (P<0.01). Remodeling was -0.56+/-0.12 in the TTA group and -1.28+/-0.09 in the placebo group (P<0.01). TTA significantly prolonged the lag time of LDL oxidation. In phytohemagglutinin stimulated PBMC, TTA significantly decreased IL-2 levels and increased IL-10 levels suggesting a marked anti-inflammatory net effect. CONCLUSIONS: Local delivery of TTA reduces coronary artery stenosis after PTCA as assessed by both angiographic, histomorphometric and ICUS examinations by influencing vessel remodeling rather than intimal hyperplasia. The underlying mechanism(s) seem to involve antioxidant and anti-inflammatory effects of this fatty acid analogue.

L34 ANSWER 3 OF 3 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-126358 [11] WPIX
CROSS REFERENCE: 2000-038952; 2000-096828; 2000-105537
DOC. NO. CPI: C2000-038393 [11]
TITLE: Use of fatty acid analogues, for treatment and/or prevention of obesity, fatty liver and hypertension
DERWENT CLASS: B05; C03
INVENTOR: BERGE R; CAPROTTI R; DAVIES B W; DILWORTH B
PATENT ASSIGNEE: (ESSO-C) EXXON CHEM PATENTS INC; (THIA-N) THIA MEDICA AS
COUNTRY COUNT: 85

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9958121	A1	19991118	(200011)*	EN	65[8]	
AU 9949366	A	19991129	(200018)	EN		
EP 1075258	A1	20010214	(200111)	EN		
BR 9910296	A	20020115	(200214)	PT	55	
JP 2002514594	W	20020521	(200236)	JA		
US 6441036	B1	20020827	(200259)	EN		
EP 1285652	A1	20030226	(200319)	EN		
EP 1284139	A1	20030219	(200321)	EN		
AU 762792	B	20030703	(200354)	EN		
EP 1075258	B1	20030820	(200356)	EN		
NZ 508045	A	20030829	(200365)	EN		
RU 2219920	C2	20031227	(200413)	RU		
ES 2207253	T3	20040516	(200434)	ES		
EP 1285652	B1	20060816	(200655)	EN		
DE 69932864	E	20060914	(200661)	DE		
DE 69932864	E	20060928	(200667)	DE		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9958121	A1	WO 1999-NO135	19990423
AU 9949366	A	AU 1999-49366	19990423
AU 762792	B	AU 1999-49366	19990423
BR 9910296	A	BR 1999-10296	19990423
DE 69932864	E	DE 1999-632645	19990423
EP 1075258	A1	EP 1999-933292	19990423
EP 1285652	A1 Div Ex	EP 1999-933292	19990423
EP 1284139	A1 Div Ex	EP 1999-933292	19990423
EP 1075258	B1	EP 1999-933292	19990423
ES 2207253	T3	EP 1999-933292	19990423
EP 1285652	B1 Div Ex	EP 1999-933292	19990423
NZ 508045	A	NZ 1999-508045	19990423
EP 1075258	A1	WO 1999-NO135	19990423
BR 9910296	A	WO 1999-NO135	19990423
JP 2002514594	W	WO 1999-NO135	19990423
US 6441036	B1	WO 1999-NO135	19990423
EP 1075258	B1	WO 1999-NO135	19990423
NZ 508045	A	WO 1999-NO135	19990423
RU 2219920	C2	JP 2000-547972	19990423
JP 2002514594	W	RU 2000-131222	19990423
RU 2219920	C2	US 2001-700061	20010127
US 6441036	B1	EP 2002-24388	19990423
EP 1284139	A1	EP 2002-24388	19990423
EP 1075258	B1	EP 2002-24388	19990423
DE 69932864	E	EP 2002-24388	19990423
EP 1285652	A1	EP 2002-24616	19990423
EP 1075258	B1	EP 2002-24616	19990423
EP 1285652	B1	EP 2002-24616	19990423
DE 69932864	E	DE 1999-632864	19990423
DE 69932864	E	EP 2002-24616	19990423

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 762792	B	Previous Publ
EP 1285652	A1	Div ex
		AU 9949366
		EP 1075258
		A

EP 1284139	A1	Div ex	EP 1075258	A
ES 2207253	T3	Based on	EP 1075258	A
EP 1285652	B1	Div ex	EP 1075258	A
EP 1075258	B1	Related to	EP 1284139	A
DE 69932645	E	Based on	EP 1284139	A
EP 1075258	B1	Related to	EP 1285652	A
AU 9949366	A	Based on	WO 9958121	A
EP 1075258	A1	Based on	WO 9958121	A
BR 9910296	A	Based on	WO 9958121	A
US 6441036	B1	Based on	WO 9958121	A
AU 762792	B	Based on	WO 9958121	A
EP 1075258	B1	Based on	WO 9958121	A
NZ 508045	A	Based on	WO 9958121	A
RU 2219920	C2	Based on	WO 9958121	A
JP 2002514594	W	Based on	WO 9958121	A1
DE 69932864	E	Based on	EP 1285652	A

PRIORITY APPLN. INFO: WO 1998-NO143 19980508

AN 2000-126358 [11] WPIX

CR 2000-038952; 2000-096828; 2000-105537

AB WO 1999058121 A1 UPAB: 20060115

NOVELTY - Novel fatty acid analogues (I), their salts, prodrugs or complexes are used for the preparation of pharmaceutical compositions.

DETAILED DESCRIPTION - The fatty acid analogues of formula (I), their salts, prodrugs or complexes are used for the preparation of pharmaceutical compositions.

CH3-(CH2)m-(Xi-CH2)n-COOR (I) n = 1-12;

m = 0-23;

i = odd number, which indicates the position of COOR; Xi = O, S, SO, SO2, Se or CH2; provided at least one Xi is not CH2; and

R = H or 1-4C alkyl.

INDEPENDENT CLAIMS are also included for: (i) novel fatty acid analogues (I); (ii) the method of modifying fat distribution and content of animals, and

hence to improve the quality of meat, milk and eggs. The method involves adding a feed product comprising the fatty acid analogues (I) to the diet of animals.

ACTIVITY - Hypotensive (claimed); Anorectic (claimed). Male obese Zucker fa/fa rats weighing 100 g are acclimatized for at least one week to 20 \pm 3 degreesC. Test sample tetracyclithioacetic acid (TTA) and control

sample palmitic acid are suspended in 0.5% (w/v) carboxymethyl cellulose. Two groups consisting of six animals each are administered with a control and test sample at a dosage of 300 mg/day/kg body weight, by gastric intubation once daily for 10 days. The blood and organs are collected after sacrificing the rats and the lipid concentration in plasma is determined. The results showed that the decrease in level of triglycerides, cholesterol and phospholipids in plasma are 72%, 73% and 71%, respectively when compared to control.

MECHANISM OF ACTION - The compound (I) increases the mitochondrial fatty acid oxidation (beta oxidation) and reduces the availability of fatty acid for esterification. Thus the compound modifies the composition of the lipids in various tissues.

USE - For treatment and/or prevention of multi metabolic syndrome such as hyperinsulinemia, insulin resistance, obesity, glucose intolerance, type 2 diabetes mellitus, dyslipidemia and/or hypertension (all claimed).

ADVANTAGE - The synthesis of triacylglycerol and cholesterol is reduced and secretion of very low density lipoprotein (VLDL) from the liver is decreased. The compound is also reduces the production of low density lipoprotein (LDL) from the liver is decreased.

The compound is also reduces the production of low density lipoprotein (LDL). Tetracyclithioacetic acid (TTA) is found to decrease hyperinsulinemia and improve insulin action on glucose utilization without increasing the body weight.

Member(0003)

ABEQ EP 1075258 A1 UPAB 20060115

NOVELTY - Novel fatty acid analogues (I), their salts, prodrugs or complexes are used for the preparation of pharmaceutical compositions.

DETAILED DESCRIPTION - The fatty acid analogues of formula (I), their salts, prodrugs or complexes are used for the preparation of pharmaceutical compositions.

CH3-(CH2)m-(Xi-CH2)n-COOR (I)

n = 1-12;

m = 0-23;

i = odd number, which indicates the position of COOR;

Xi = O, S, SO, SO2, Se or CH2; provided at least one Xi is not

CH2; and

R = H or 1-4C alkyl.

INDEPENDENT CLAIMS are also included for:

(i) novel fatty acid analogues (I);

(ii) the method of modifying fat distribution and content of animals, and hence to improve the quality of meat, milk and eggs. The method involves adding a feed product comprising the fatty acid analogues (I) to the diet of animals.

ACTIVITY - Hypotensive (claimed); Anorectic (claimed).

Male obese Zucker fa/fa rats weighing 100 g are acclimatized for at least one week to 20 \pm 3 degreesC. Test sample

tetracyclithioacetic acid (TTA) and control sample palmitic acid are suspended in 0.5% (w/v) carboxymethyl cellulose. Two groups consisting of six animals each are administered with a control and test sample at a dosage of 300 mg/day/kg body weight, by gastric intubation once daily for 10 days. The blood and organs are collected after sacrificing the rats and the lipid concentration in plasma is determined. The results showed that the decrease in level of triglycerides, cholesterol and phospholipids in plasma are 72%, 73% and 71%, respectively when compared to control.


MECHANISM OF ACTION - The compound (I) increases the mitochondrial fatty acid oxidation (beta oxidation) and reduces the availability of fatty acid for esterification. Thus the compound modifies the composition of the lipids in various tissues.

USE - For treatment and/or prevention of multi metabolic syndrome such as hyperinsulinemia, insulin resistance, obesity, glucose intolerance, type 2 diabetes mellitus, dyslipidemia and/or hypertension (all claimed).

ADVANTAGE - The synthesis of triacylglycerol and cholesterol is reduced and secretion of very low density lipoprotein (VLDL) from the liver is decreased. The compound is also reduces the production of low density lipoprotein (LDL). Tetracyclithioacetic acid (TTA) is found to decrease hyperinsulinemia and improve insulin action on glucose utilization without increasing the body weight.

FILE 'HOME' ENTERED AT 16:01:40 ON 22 JUN 2007


L1 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 21
CONNECT IS X2 RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12


STEREO ATTRIBUTES: NONE
L2 (520)SEA FILE=REGISTRY SSS FUL L1
L3 STR



VAR G1=CH2/S/SE/O
NODE ATTRIBUTES:
NSPEC IS RC AT 21
CONNECT IS X2 RC AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L4 STR



VAR G1=CH2/S/SE/O
NODE ATTRIBUTES:
NSPEC IS RC AT 21
CONNECT IS X2 RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L5 109 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)
L6 41 SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND P=>1

(FILE 'REGISTRY' ENTERED AT 15:34:06 ON 22 JUN 2007)
ACT LAOL5914D/A

L1 STR
L2 (520)SEA SSS FUL L1
L3 STR
L4 STR
L5 109 SEA SUB=L2 SSS FUL (L3 OR L4)
L6 41 SEA ABB=ON PLU=ON L5 AND P=>1

FILE 'REGISTRY' ENTERED AT 15:36:55 ON 22 JUN 2007
D QUE STAT

L7 FILE 'CAPLUS' ENTERED AT 15:36:55 ON 22 JUN 2007
16 SEA ABB=ON PLU=ON L6
DEL SEL Y
SEL HIT L7 1-16 RN
D L7 1-16 IBIB ABS HITSTR

L8 FILE 'CAOLD' ENTERED AT 15:37:44 ON 22 JUN 2007
0 SEA ABB=ON PLU=ON L6

L9 FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:38:00 ON 22 JUN 2007
0 SEA ABB=ON PLU=ON L6

L10 FILE 'CAPLUS' ENTERED AT 15:38:15 ON 22 JUN 2007
39 SEA ABB=ON PLU=ON L5
L11 23 SEA ABB=ON PLU=ON L10 NOT L7
SEL HIT L11 1-23 RN
L12 18 SEA ABB=ON PLU=ON L11 AND PATENT/DT
L13 15 SEA ABB=ON PLU=ON L12 AND (PY<2002 OR AY<2002 OR

L14 5 SEA ABB=ON PIJ=ON L11 NOT L12
L15 1 SEA ABB=ON PIJ=ON L14 NOT PY<2002
L16 16 SEA ABB=ON PIJ=ON L13 OR L15
SEL L16 1-16 HIT RN
D L16 1-16 IBIB ABS HITSTR

FILE 'CAOLD' ENTERED AT 15:44:31 ON 22 JUN 2007
L17 2 SEA ABB=ON PIJ=ON L5
D 1-2

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:44:47 ON 22 JUN 2007
L18 0 SEA ABB=ON PIJ=ON L5

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIX, JAPIO, PASCAL, DISSABS'
ENTERED AT 15:45:02 ON 22 JUN 2007
L19 22599 SEA ABB=ON PIJ=ON "MILLER A"?/AU
L20 2001 SEA ABB=ON PIJ=ON "JORGENSEN M"?/AU
L21 1106 SEA ABB=ON PIJ=ON "BERGE R"?/AU
L22 144 SEA ABB=ON PIJ=ON "SKORVE J"?/AU
L23 2 SEA ABB=ON PIJ=ON L19 AND L20 AND L21 AND L22
L24 51 SEA ABB=ON PIJ=ON L19 AND L20 OR L21 OR L22
L25 2 SEA ABB=ON PIJ=ON L20 AND (L21 OR L22)
L26 115 SEA ABB=ON PIJ=ON L21 AND L22
L27 428 SEA ABB=ON PIJ=ON ((L19 OR L20 OR L21 OR L22) OR L24 OR L26) AND (PHG OR POLAR HEAD OR PHOSPHOLIPID? OR LYSOPHOSPHO LIPID? OR (PHOSPHO OR LYSOPHOSPHO)(W) LIPID? OR CERAMIDE OR MONACYLGLYCEROL OR TRIACYLGLYCEROL OR DIACYLGLYCEROL OR (MONACYL OR TRIACYL OR DIACYL)(W) GLYCEROL OR W(W) LINK?(W) (HG OR HEAD GROUP))

L28 983 SEA ABB=ON PIJ=ON ((L19 OR L20 OR L21 OR L22) OR L24 OR L26) AND (PHOSPHATIDYL? OR LIPID OR (PC OR PE OR PS OR PI OR PG OR PA)(S) PHOSPHATIDYL?)

L29 140 SEA ABB=ON PIJ=ON (L27 OR L28) AND (SULFUR? OR SULPHUR? OR SULFAT? OR SULPHAT?)

L30 89 SEA ABB=ON PIJ=ON L29 AND (TREAT? OR THERAP? OR PREVENT?)

L31 59 SEA ABB=ON PIJ=ON L29 AND INHIBIT?

L32 3 SEA ABB=ON PIJ=ON (L30 OR L31) AND (TOPICAL? OR PARENTAL? OR IV OR (I-OR INTRA)(W) OR VENOUS?) OR INTRA(W) (ABDOMEN OR ABDOMIN? OR PERITONEAL?) OR INTRAPERITONEAL? OR PERITONEAL?)

L33 4 SEA ABB=ON PIJ=ON L23 OR L25 OR L32
L34 3 DUP REM L33 (1 DUPLICATE REMOVED)
D 1-3 IBIB ABS

FILE 'HOME' ENTERED AT 16:01:40 ON 22 JUN 2007
D QUE L6

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3
DICTIONARY FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 21 Jun 2007 (20070621/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE CAOLD
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE MEDLINE

FILE LAST UPDATED: 21 Jun 2007 (20070621/UP). FILE COVERS 1950 TO DA

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 20 June 2007 (20070620/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE EMBASE

FILE COVERS 1974 TO 22 JUN 2007 (20070622/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX

FILE LAST UPDATED:

MOST RECENT THOMSON SCIENTIFIC UPDATE: 20 JUN 2007 <20070620/UP>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> New relaoded DWPI Learn File (LWPI) available as well <<<

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<
SEE ONLINE NEWS and

http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.

>>> IPC Reform backfile reclassification has been loaded to 31 May 2007. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC and 20060601/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stdatabases/details/ipc_reform.html a
<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE

http://www.stn-international.de/stdatabases/details/dwpi_r.html <<<

FILE JAPIO

FILE LAST UPDATED: 19 JUN 2007 <20070619/UP>

FILE COVERS APRIL 1973 TO FEBRUARY 22, 2007

>>> GRAPHIC IMAGES AVAILABLE <<<

FILE PASCAL

FILE LAST UPDATED: 18 JUN 2007 <20070618/UP>

FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE DISSABS

FILE COVERS 1861 TO 25 MAY 2007 (20070525/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

FILE HOME